Skip to main content
Erschienen in: Investigational New Drugs 4/2012

01.08.2012 | PRECLINICAL STUDIES

Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells

verfasst von: Zahid M. Delwar, Dimitrios Avramidis, Elna Follin, Yan Hua, Åke Siden, Mabel Cruz, Kajsa M. Paulsson, Juan Sebastian Yakisich

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

Gliomas are the most common primary brain tumor, and their treatment is still a challenge. Here, we evaluated the antiproliferative effect of a novel combination of two potent oxidative stress enhancers: menadione (M) and sodium orthovanadate (SO). We observed both short-term and prolonged growth inhibitory effects of M or SO alone as well as in combination (M:SO) on DBTRG.05MG human glioma cells. A stronger antiproliferative effect was observed in the short-term proliferation assay with the M:SO combination compared to either investigated agent alone. In the long-term proliferation assay, a 10-day exposure to M:SO at concentrations of 10 μM:17.5 μM or 17.5 μM:10 μM was enough to kill 100% of the cells; no cell regrowth was observed after re-incubation in drug-free media. When used in combination, the single concentration of M and SO could be decreased by 2.5- to 5-fold of those used for each experimental drug alone and still obtain a similar antiproliferative effect. The underlying molecular mechanism was investigated by co-incubating M:SO with dithiothreitol (DTT) and genistein. Both substances partially neutralized the effects of the M:SO combination, showing additive effects. This observation suggests a role of oxidative stress and tyrosine kinase stimulation in the M:SO cytotoxic effect. Our results indicate that M:SO combination is an attractive alternative for glioma treatment that encourages further study. The neutralizing effects of genistein and DTT reveal a possibility for their use in the minimization of potential M:SO systemic toxicity.
Literatur
1.
Zurück zum Zitat Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST (2009) Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer 46:96–107CrossRefPubMed Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST (2009) Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer 46:96–107CrossRefPubMed
2.
Zurück zum Zitat Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst 101:1721–1724CrossRefPubMed Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst 101:1721–1724CrossRefPubMed
3.
Zurück zum Zitat Donelli MG, Zucchetti M, D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251–260CrossRefPubMed Donelli MG, Zucchetti M, D’Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251–260CrossRefPubMed
4.
Zurück zum Zitat Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–1106CrossRefPubMed Juillerat-Jeanneret L (2008) The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today 13:1099–1106CrossRefPubMed
5.
Zurück zum Zitat Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6:1017–1032CrossRefPubMed Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6:1017–1032CrossRefPubMed
6.
Zurück zum Zitat Jiang H, Shang X, Wu H, Huang G, Wang Y, Al-Holou S, Gautam SC, Chopp M (2010) Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res 35:152–161CrossRefPubMed Jiang H, Shang X, Wu H, Huang G, Wang Y, Al-Holou S, Gautam SC, Chopp M (2010) Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res 35:152–161CrossRefPubMed
7.
Zurück zum Zitat Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, Mahmood A, Chopp M (2009) Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 65:1087–1096CrossRefPubMed Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, Mahmood A, Chopp M (2009) Effect of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery 65:1087–1096CrossRefPubMed
8.
Zurück zum Zitat Cruz M, Siden Å, Tasat DR, Yakisich JS (2010) Are all glioma cells cancer stem cells? J Cancer Sci Ther 2:100–106CrossRef Cruz M, Siden Å, Tasat DR, Yakisich JS (2010) Are all glioma cells cancer stem cells? J Cancer Sci Ther 2:100–106CrossRef
9.
Zurück zum Zitat Laks DR, Visnyei K, Kornblum HI (2010) Brain tumor stem cells as therapeutic targets in models of glioma. Yonsei Med J 51:633–640CrossRefPubMed Laks DR, Visnyei K, Kornblum HI (2010) Brain tumor stem cells as therapeutic targets in models of glioma. Yonsei Med J 51:633–640CrossRefPubMed
10.
Zurück zum Zitat Yakisich JS, Ohlsson Lindblom I, Siden A, Cruz MH (2009) Rapid inhibition of ongoing DNA synthesis in human glioma tissue by genistein. Oncol Rep 22:569–574CrossRefPubMed Yakisich JS, Ohlsson Lindblom I, Siden A, Cruz MH (2009) Rapid inhibition of ongoing DNA synthesis in human glioma tissue by genistein. Oncol Rep 22:569–574CrossRefPubMed
11.
Zurück zum Zitat Matzno S, Yamaguchi Y, Akiyoshi T, Nakabayashi T, Matsuyama K (2008) An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull 31:1270–1273CrossRefPubMed Matzno S, Yamaguchi Y, Akiyoshi T, Nakabayashi T, Matsuyama K (2008) An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull 31:1270–1273CrossRefPubMed
12.
Zurück zum Zitat Chlebowski RT, Dietrich M, Akman S, Block JB (1985) Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69:527–532PubMed Chlebowski RT, Dietrich M, Akman S, Block JB (1985) Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69:527–532PubMed
13.
Zurück zum Zitat Akman SA, Doroshow JH, Dietrich MF, Chlebowski RT, Block JS (1987) Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210. J Pharmacol Exp Ther 240:486–491PubMed Akman SA, Doroshow JH, Dietrich MF, Chlebowski RT, Block JS (1987) Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210. J Pharmacol Exp Ther 240:486–491PubMed
14.
Zurück zum Zitat Duthie SJ, Grant MH (1989) The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells. Biochem Pharmacol 38:1247–1255CrossRefPubMed Duthie SJ, Grant MH (1989) The toxicity of menadione and mitozantrone in human liver-derived Hep G2 hepatoma cells. Biochem Pharmacol 38:1247–1255CrossRefPubMed
15.
Zurück zum Zitat Okayasu H, Ishihara M, Satoh K, Sakagami H (2001) Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res 21:2387–2392PubMed Okayasu H, Ishihara M, Satoh K, Sakagami H (2001) Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res 21:2387–2392PubMed
16.
Zurück zum Zitat Tetef M, Margolin K, Ahn C, Akman S, Chow W, Leong L, Morgan RJ Jr, Raschko J, Somlo G, Doroshow JH (1995) Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs 13:157–162CrossRefPubMed Tetef M, Margolin K, Ahn C, Akman S, Chow W, Leong L, Morgan RJ Jr, Raschko J, Somlo G, Doroshow JH (1995) Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs 13:157–162CrossRefPubMed
17.
Zurück zum Zitat Akiyoshi T, Matzno S, Sakai M, Okamura N, Matsuyama K (2009) The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. Cancer Chemother Pharmacol 65:143–150CrossRefPubMed Akiyoshi T, Matzno S, Sakai M, Okamura N, Matsuyama K (2009) The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. Cancer Chemother Pharmacol 65:143–150CrossRefPubMed
18.
Zurück zum Zitat Baran I, Ganea C, Scordino A, Musumeci F, Barresi V, Tudisco S, Privitera S, Grasso R, Condorelli DF, Ursu I (2010) Effects of menadione, hydrogen peroxide, and quercetin on apoptosis and delayed luminescence of human leukemia Jurkat T-cells. Cell Biochem Biophys 58:169–179CrossRefPubMed Baran I, Ganea C, Scordino A, Musumeci F, Barresi V, Tudisco S, Privitera S, Grasso R, Condorelli DF, Ursu I (2010) Effects of menadione, hydrogen peroxide, and quercetin on apoptosis and delayed luminescence of human leukemia Jurkat T-cells. Cell Biochem Biophys 58:169–179CrossRefPubMed
19.
Zurück zum Zitat Oztopçu P, Kabadere S, Mercangoz A, Uyar R (2004) Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 104:106–110PubMed Oztopçu P, Kabadere S, Mercangoz A, Uyar R (2004) Comparison of vitamins K1, K2 and K3 effects on growth of rat glioma and human glioblastoma multiforme cells in vitro. Acta Neurol Belg 104:106–110PubMed
20.
Zurück zum Zitat Prasad KN, Edwards-Prasad J, Sakamoto A (1981) Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. Life Sci 29:1387–1392CrossRefPubMed Prasad KN, Edwards-Prasad J, Sakamoto A (1981) Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. Life Sci 29:1387–1392CrossRefPubMed
21.
Zurück zum Zitat Vita MF, Nagachar N, Avramidis D, Delwar ZM, Cruz MH, Siden A, Paulsson KM, Yakisich JS (2010) Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C. Invest New Drugs, in press Vita MF, Nagachar N, Avramidis D, Delwar ZM, Cruz MH, Siden A, Paulsson KM, Yakisich JS (2010) Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C. Invest New Drugs, in press
22.
Zurück zum Zitat Avramidis D, Cruz M, Sidén Å, Tasat DR, Yakisich JS (2009) Regrowth concentration zero (RC0) as complementary endpoint parameter to evaluate compound candidates during preclinical drug development for cancer treatment. J Cancer Sci Ther 1:019–024CrossRef Avramidis D, Cruz M, Sidén Å, Tasat DR, Yakisich JS (2009) Regrowth concentration zero (RC0) as complementary endpoint parameter to evaluate compound candidates during preclinical drug development for cancer treatment. J Cancer Sci Ther 1:019–024CrossRef
23.
Zurück zum Zitat Brière JJ, Schlemmer D, Chretien D, Rustin P (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316:1138–1142CrossRefPubMed Brière JJ, Schlemmer D, Chretien D, Rustin P (2004) Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316:1138–1142CrossRefPubMed
24.
Zurück zum Zitat Floreani M, Carpenedo F (1992) One- and two-electron reduction of menadione in guinea-pig and rat cardiac tissue. Gen Pharmacol 23:757–762CrossRefPubMed Floreani M, Carpenedo F (1992) One- and two-electron reduction of menadione in guinea-pig and rat cardiac tissue. Gen Pharmacol 23:757–762CrossRefPubMed
25.
Zurück zum Zitat Hu OY, Wu CY, Chan WK, Wu FY, Whang-Peng J (1996) A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. Biopharm Drug Dispos 17:493–499CrossRefPubMed Hu OY, Wu CY, Chan WK, Wu FY, Whang-Peng J (1996) A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. Biopharm Drug Dispos 17:493–499CrossRefPubMed
26.
Zurück zum Zitat Lamson DW, Plaza SM (2003) The anticancer effects of vitamin K. Altern Med Rev 8:303–318PubMed Lamson DW, Plaza SM (2003) The anticancer effects of vitamin K. Altern Med Rev 8:303–318PubMed
27.
Zurück zum Zitat Ham SW, Song JH, Kim HI, Jin S (2000) Mechanism of cell cycle arrest by menadione. Bull Korean Chem Soc 21:1173–1174 Ham SW, Song JH, Kim HI, Jin S (2000) Mechanism of cell cycle arrest by menadione. Bull Korean Chem Soc 21:1173–1174
28.
Zurück zum Zitat Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A (2008) The effect of vanadyl sulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol J Pathol 59:3–8PubMed Holko P, Ligeza J, Kisielewska J, Kordowiak AM, Klein A (2008) The effect of vanadyl sulphate (VOSO4) on autocrine growth of human epithelial cancer cell lines. Pol J Pathol 59:3–8PubMed
29.
Zurück zum Zitat Kordowiak AM, Klein A, Goc A, Dabroś W (2007) Comparison of the effect of VOSO4, Na3VO4 and NaVO3 on proliferation, viability and morphology of H35-19 rat hepatoma cell line. Pol J Pathol 58:51–57PubMed Kordowiak AM, Klein A, Goc A, Dabroś W (2007) Comparison of the effect of VOSO4, Na3VO4 and NaVO3 on proliferation, viability and morphology of H35-19 rat hepatoma cell line. Pol J Pathol 58:51–57PubMed
30.
Zurück zum Zitat Klein A, Holko P, Ligeza J, Kordowiak AM (2008) Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol Krakow 56:115–121CrossRefPubMed Klein A, Holko P, Ligeza J, Kordowiak AM (2008) Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol Krakow 56:115–121CrossRefPubMed
31.
Zurück zum Zitat Capella LS, Gefé MR, Silva EF, Affonso-Mitidieri O, Lopes AG, Rumjanek VM, Capella MA (2002) Mechanisms of vanadate-induced cellular toxicity: role of cellular glutathione and NADPH. Arch Biochem Biophys 406:65–72CrossRefPubMed Capella LS, Gefé MR, Silva EF, Affonso-Mitidieri O, Lopes AG, Rumjanek VM, Capella MA (2002) Mechanisms of vanadate-induced cellular toxicity: role of cellular glutathione and NADPH. Arch Biochem Biophys 406:65–72CrossRefPubMed
32.
Zurück zum Zitat Capella MA, Capella LS, Valente RC, Gefé M, Lopes AG (2007) Vanadate-induced cell death is dissociated from H2O2 generation. Cell Biol Toxicol 23:413–420CrossRefPubMed Capella MA, Capella LS, Valente RC, Gefé M, Lopes AG (2007) Vanadate-induced cell death is dissociated from H2O2 generation. Cell Biol Toxicol 23:413–420CrossRefPubMed
33.
Zurück zum Zitat Srivastava AK, Mehdi MZ (2005) Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 22:2–13CrossRefPubMed Srivastava AK, Mehdi MZ (2005) Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 22:2–13CrossRefPubMed
34.
Zurück zum Zitat Byrne AR, Kosta L (1978) Vanadium in foods and in human body fluids and tissues. Sci Total Environ 10:17–30CrossRefPubMed Byrne AR, Kosta L (1978) Vanadium in foods and in human body fluids and tissues. Sci Total Environ 10:17–30CrossRefPubMed
35.
Zurück zum Zitat Srivastava AK (2000) Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206:177–182CrossRefPubMed Srivastava AK (2000) Anti-diabetic and toxic effects of vanadium compounds. Mol Cell Biochem 206:177–182CrossRefPubMed
36.
Zurück zum Zitat Uthus EO, Nielsen FH (1990) Effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. Magnes Trace Elem 9:219–226PubMed Uthus EO, Nielsen FH (1990) Effect of vanadium, iodine and their interaction on growth, blood variables, liver trace elements and thyroid status indices in rats. Magnes Trace Elem 9:219–226PubMed
37.
Zurück zum Zitat Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E (2001) Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diab Metab Res Rev 17:55–66CrossRef Shafrir E, Spielman S, Nachliel I, Khamaisi M, Bar-On H, Ziv E (2001) Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the Psammomys obesus gerbil. Diab Metab Res Rev 17:55–66CrossRef
38.
Zurück zum Zitat Gordon JA (1991) Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Meth Enzymol 201:477–482CrossRefPubMed Gordon JA (1991) Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Meth Enzymol 201:477–482CrossRefPubMed
39.
Zurück zum Zitat Abdelmohsen K, Patak P, Von Montfort C, Melchheier I, Sies H, Klotz LO (2004) Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation. Meth Enzymol 378:258–272CrossRefPubMed Abdelmohsen K, Patak P, Von Montfort C, Melchheier I, Sies H, Klotz LO (2004) Signaling effects of menadione: from tyrosine phosphatase inactivation to connexin phosphorylation. Meth Enzymol 378:258–272CrossRefPubMed
40.
Zurück zum Zitat Nakayama T, Asami S, Ono S, Miura M, Hayasaka M, Yoshida Y, Toriyama M, Motohashi S, Suzuki T (2009) Effect of cell differentiation for neuroblastoma by vitamin K analogs. Jpn J Clin Oncol 39:251–259CrossRefPubMed Nakayama T, Asami S, Ono S, Miura M, Hayasaka M, Yoshida Y, Toriyama M, Motohashi S, Suzuki T (2009) Effect of cell differentiation for neuroblastoma by vitamin K analogs. Jpn J Clin Oncol 39:251–259CrossRefPubMed
41.
Zurück zum Zitat McDonagh B, Sheehan D (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: proteomic identification of target proteins. Proteomics 7:3395–3403CrossRefPubMed McDonagh B, Sheehan D (2007) Effect of oxidative stress on protein thiols in the blue mussel Mytilus edulis: proteomic identification of target proteins. Proteomics 7:3395–3403CrossRefPubMed
42.
Zurück zum Zitat Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T (2000) A redox signaling mechanism for density-dependent inhibition of cell growth. J Biol Chem 275:38891–38899CrossRefPubMed Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, Galeotti T (2000) A redox signaling mechanism for density-dependent inhibition of cell growth. J Biol Chem 275:38891–38899CrossRefPubMed
43.
Zurück zum Zitat Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319CrossRefPubMed Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319CrossRefPubMed
44.
Zurück zum Zitat Sankar A, Thomas DG, Darling JL (1999) Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10:179–185CrossRefPubMed Sankar A, Thomas DG, Darling JL (1999) Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anticancer Drugs 10:179–185CrossRefPubMed
45.
Zurück zum Zitat Sakai A (1997) Orthovanadate, an inhibitor of protein tyrosine phosphatases, acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation. Carcinogenesis 18:1395–1399CrossRefPubMed Sakai A (1997) Orthovanadate, an inhibitor of protein tyrosine phosphatases, acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation. Carcinogenesis 18:1395–1399CrossRefPubMed
46.
Zurück zum Zitat Cortizo AM, Bruzzone L, Molinuevo S, Etcheverry SB (2000) A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines. Toxicology 147:89–99CrossRefPubMed Cortizo AM, Bruzzone L, Molinuevo S, Etcheverry SB (2000) A possible role of oxidative stress in the vanadium-induced cytotoxicity in the MC3T3E1 osteoblast and UMR106 osteosarcoma cell lines. Toxicology 147:89–99CrossRefPubMed
47.
Zurück zum Zitat Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ (2010) Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 119:157–175CrossRefPubMed Navis AC, van den Eijnden M, Schepens JT, Hooft van Huijsduijnen R, Wesseling P, Hendriks WJ (2010) Protein tyrosine phosphatases in glioma biology. Acta Neuropathol 119:157–175CrossRefPubMed
48.
Zurück zum Zitat Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW (1991) Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41:1283–1292CrossRefPubMed Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW (1991) Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 41:1283–1292CrossRefPubMed
49.
Zurück zum Zitat Lim D, Morgan RJJ, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Doroshow JH (2005) Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest New Drugs 23:235–239CrossRefPubMed Lim D, Morgan RJJ, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Doroshow JH (2005) Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest New Drugs 23:235–239CrossRefPubMed
50.
Zurück zum Zitat Öztopcu-Vatan P, Kabadere S (2007) The effects of menadione on rat glial cell proliferation. J Neurol Sci Turk 24:25–28 Öztopcu-Vatan P, Kabadere S (2007) The effects of menadione on rat glial cell proliferation. J Neurol Sci Turk 24:25–28
51.
Zurück zum Zitat Hasegawa Y, Morioka M, Hasegawa S, Matsumoto J, Kawano T, Kai Y, Yano S, Fukunaga K, Kuratsu J (2006) Therapeutic time window and dose dependence of neuroprotective effects of sodium orthovanadate following transient middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 317:875–881CrossRefPubMed Hasegawa Y, Morioka M, Hasegawa S, Matsumoto J, Kawano T, Kai Y, Yano S, Fukunaga K, Kuratsu J (2006) Therapeutic time window and dose dependence of neuroprotective effects of sodium orthovanadate following transient middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 317:875–881CrossRefPubMed
52.
Zurück zum Zitat Száraz P, Bánhegyi G, Benedetti A (2010) Altered redox state of luminal pyridine nucleotides facilitates the sensitivity towards oxidative injury and leads to endoplasmic reticulum stress dependent autophagy in HepG2 cells. Int J Biochem Cell Biol 42:157–166CrossRefPubMed Száraz P, Bánhegyi G, Benedetti A (2010) Altered redox state of luminal pyridine nucleotides facilitates the sensitivity towards oxidative injury and leads to endoplasmic reticulum stress dependent autophagy in HepG2 cells. Int J Biochem Cell Biol 42:157–166CrossRefPubMed
53.
Zurück zum Zitat Niemczyk E, Majczak A, Hallmann A, Kedzior J, Woźniak M, Wakabayashi T (2004) A possible involvement of plasma membrane NAD(P)H oxidase in the switch mechanism of the cell death mode from apoptosis to necrosis in menadione-induced cell injury. Acta Biochim Polonica 51:1015–1022 Niemczyk E, Majczak A, Hallmann A, Kedzior J, Woźniak M, Wakabayashi T (2004) A possible involvement of plasma membrane NAD(P)H oxidase in the switch mechanism of the cell death mode from apoptosis to necrosis in menadione-induced cell injury. Acta Biochim Polonica 51:1015–1022
54.
Zurück zum Zitat Wochna A, Niemczyk E, Kurono C, Masaoka M, Kedzior J, Słomińska E, Lipiński M, Wakabayashi T (2007) A possible role of oxidative stress in the switch mechanism of the cell death mode from apoptosis to necrosis-studies on rho0 cells. Mitochondrion 7:119–124CrossRefPubMed Wochna A, Niemczyk E, Kurono C, Masaoka M, Kedzior J, Słomińska E, Lipiński M, Wakabayashi T (2007) A possible role of oxidative stress in the switch mechanism of the cell death mode from apoptosis to necrosis-studies on rho0 cells. Mitochondrion 7:119–124CrossRefPubMed
55.
Zurück zum Zitat Gilloteaux J, Jamison JM, Lorimer HE, Jarjoura D, Taper HS, Calderon PB, Neal DR, Summers JL (2004) Autoschizis: a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment. Nuclear and DNA degradation. Tissue Cell 36:197–209CrossRefPubMed Gilloteaux J, Jamison JM, Lorimer HE, Jarjoura D, Taper HS, Calderon PB, Neal DR, Summers JL (2004) Autoschizis: a new form of cell death for human ovarian carcinoma cells following ascorbate:menadione treatment. Nuclear and DNA degradation. Tissue Cell 36:197–209CrossRefPubMed
56.
Zurück zum Zitat Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc Calderon P (2003) The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 38:451–457CrossRefPubMed Verrax J, Cadrobbi J, Delvaux M, Jamison JM, Gilloteaux J, Summers JL, Taper HS, Buc Calderon P (2003) The association of vitamins C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Eur J Med Chem 38:451–457CrossRefPubMed
57.
Zurück zum Zitat Morita A, Yamamoto S, Wang B, Tanaka K, Suzuki N, Aoki S, Ito A, Nanao T, Ohya S, Yoshino M (2010) Sodium orthovanadate inhibits p53-mediated apoptosis. Cancer Res 70:257–265CrossRefPubMed Morita A, Yamamoto S, Wang B, Tanaka K, Suzuki N, Aoki S, Ito A, Nanao T, Ohya S, Yoshino M (2010) Sodium orthovanadate inhibits p53-mediated apoptosis. Cancer Res 70:257–265CrossRefPubMed
58.
Zurück zum Zitat Morita A, Zhu J, Suzuki N, Enomoto A, Matsumoto Y, Tomita M, Suzuki T, Ohtomo K, Hosoi Y (2006) Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53. Cell Death Differ 13:499–511CrossRefPubMed Morita A, Zhu J, Suzuki N, Enomoto A, Matsumoto Y, Tomita M, Suzuki T, Ohtomo K, Hosoi Y (2006) Sodium orthovanadate suppresses DNA damage-induced caspase activation and apoptosis by inactivating p53. Cell Death Differ 13:499–511CrossRefPubMed
59.
Zurück zum Zitat Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18:431–439CrossRefPubMed Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I (1994) The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18:431–439CrossRefPubMed
60.
Zurück zum Zitat Friso A, Tomanin R, Salvalaio M, Scarpa M (2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159:1082–1091CrossRefPubMed Friso A, Tomanin R, Salvalaio M, Scarpa M (2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159:1082–1091CrossRefPubMed
61.
Zurück zum Zitat Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, Brem H (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643–650CrossRefPubMed Brem S, Tyler B, Li K, Pradilla G, Legnani F, Caplan J, Brem H (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643–650CrossRefPubMed
62.
Zurück zum Zitat McGirt MJ, Brem H (2010) Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 17:1729–1731CrossRefPubMed McGirt MJ, Brem H (2010) Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy. Ann Surg Oncol 17:1729–1731CrossRefPubMed
63.
Zurück zum Zitat Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J, Neuro-oncology Club of the French Society of Neurosurgery (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740–1746CrossRefPubMed Menei P, Metellus P, Parot-Schinkel E, Loiseau H, Capelle L, Jacquet G, Guyotat J, Neuro-oncology Club of the French Society of Neurosurgery (2010) Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 17:1740–1746CrossRefPubMed
64.
Zurück zum Zitat Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H (2010) Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 66:530–537CrossRefPubMed Recinos VR, Tyler BM, Bekelis K, Sunshine SB, Vellimana A, Li KW, Brem H (2010) Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 66:530–537CrossRefPubMed
65.
Zurück zum Zitat Depape-Brigger D, Goldman H, Scriver CR, Delvin E, Mamer O (1977) The in vivo use of dithiothreitol in cystinosis. Pediatr Res 11:124–131CrossRefPubMed Depape-Brigger D, Goldman H, Scriver CR, Delvin E, Mamer O (1977) The in vivo use of dithiothreitol in cystinosis. Pediatr Res 11:124–131CrossRefPubMed
66.
Zurück zum Zitat Klonne DR, Johnson DR (1985) Renal cortical mercury distribution following dithiothreitol administration. J Toxicol Environ Health 16:137–145CrossRefPubMed Klonne DR, Johnson DR (1985) Renal cortical mercury distribution following dithiothreitol administration. J Toxicol Environ Health 16:137–145CrossRefPubMed
Metadaten
Titel
Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells
verfasst von
Zahid M. Delwar
Dimitrios Avramidis
Elna Follin
Yan Hua
Åke Siden
Mabel Cruz
Kajsa M. Paulsson
Juan Sebastian Yakisich
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9680-y

Weitere Artikel der Ausgabe 4/2012

Investigational New Drugs 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.